Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

US Government Forces US Healthcare Company to Divest Investment From China's iCarbonX

publication date: Apr 5, 2019

For the first time, there is a report that the US government is forcing a US-based healthcare company to divest an investment from a China investor. PatientsLikeMe is a Boston social media company that allows people with a similar disease to communicate with each other. In 2017, the company raised $100+ million from iCarbonX, the AI/big data company formed by Jun Wang, previously CEO of BGI. According to CNBC, the Committee on Foreign Investment in the United States has forced PatientsLikeMe to return the investment. No official report has been released but PatientsLikeMe is said to be looking for a buyer. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital